Page last updated: 2024-12-08
iduronate 2-sulfate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
iduronate 2-sulfate: found in heparan sulfate; RN given refers to (L)-isomer; RN for cpd without isomeric designation not avail 3/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 174769 |
SCHEMBL ID | 782359 |
MeSH ID | M0184873 |
Synonyms (9)
Synonym |
---|
l-iduronic acid, 2-(hydrogen sulfate) |
iduronate 2-sulfate |
2-o-sulfo-l-iduronic acid |
(2r,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-sulfooxyhexanoic acid |
iduronate 2-sulphate |
89846-17-3 |
SCHEMBL782359 |
(2r,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-(sulfooxy)hexanoic acid |
AKOS040752065 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (41.67) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 2 (16.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.95
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.95) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |